MATJAž ZWITTER, M.D., M.SC.; JOžE DRINOVEC, Ph.D.; MIRKO DUBRAVČIĆ, M.D.; ALENKA VODNIK, M.D.; JELKA PETRIČ-GRABNAR, M.D.; MAJDA DOLNIČAR, M.D.; MIODRAG KONSTANTINOVIĆ, Ph.D.; žARKA žEMVA, M.SC.
The outlook for patients with Hodgkin disease in relapse after receiving several combinations of cytotoxic drugs is still unfavorable. Our preliminary experience with cyclosporine indicates that the introduction of a new drug and a new therapeutic approach deserves further attention in Hodgkin disease, and possibly in other lymphoproliferative disorders.
Ten patients with Hodgkin disease who had a biopsy-proven relapse after first- and second-line chemotherapy participated in the study (Table 1). All patients had measurable extranodal disease with B symptoms, normal renal function, and gave informed consent for a new treatment.
Cyclosporine was taken orally twice daily, diluted in milk or
ZWITTER M, DRINOVEC J, DUBRAVČIĆ M, VODNIK A, PETRIČ-GRABNAR J, DOLNIČAR M, et al. Cyclosporine May Alleviate B Symptoms and Induce a Remission of Heavily Pretreated Hodgkin Disease: A Preliminary Report. Ann Intern Med. ;106:843–844. doi: 10.7326/0003-4819-106-6-843
Download citation file:
Published: Ann Intern Med. 1987;106(6):843-844.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use